Sylentis to Start Clinical Trial of SYL040012 for the Treatment of Ocular Hypertension
August 27, 2009
Sylentis has announced that the organization expects to dose the first patients in the phase I study of its glaucoma-associated ocular hypertension drug SYL040012 in Spain around the end of September. Sylentis received approval last month from the Spanish regulatory agency to begin trials.
This Phase I study will take place at the Unit for Phase I Clinical Assays at the Clínica Universitaria de Navarra on healthy volunteers. The goal of this trial is to ensure the safety of the agent.
SYL040012 is a siRNA which is specific for the adrenergic receptor beta-2. This experimental agent has shown in vivo efficacy reducing intraocular pressure as well as a prophylactic effect on glaucoma prevention in animal models according to the company’s website.
Jump down to form below to submit your own comments